Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the
literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” …

Background Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute
myeloid leukaemia characterised by the presence of the PML–RARA fusion transcript. The …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Much evidence has accumulated in the literature over the last fifteen years that indicates
vitamin A has a role in metabolic disease prevention and causation. This literature proposes …

The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been
shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients …

Retinoic acid (RA), the major bioactive metabolite of retinol or vitamin A, induces a spectrum
of pleiotropic effects in cell growth and differentiation that are relevant for embryonic …

Similar to normal tissue, many tumors have a hierarchical organization where tumorigenic
cancer stem cells (CSCs) differentiate into non-tumorigenic progenies. A host of studies …

Constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem
duplication (ITD) of the juxtamembrane region or by point mutations in the second tyrosine …

We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to
ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) …